Andrew Combs, Chief Chemistry Officer at Prelude Therapeutics Inc (PRLD), bought 100,000 shares at $0.69 ($69K) on 2025-03-25, disclosed to the SEC on 2025-03-27.
Open-market purchase of $69k PRLD by Chief Chemistry Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| PRLD | BUY | 2020-09-29 | $19K | — | Filing → |